Cargando…

Postoperative Chemoradiotherapy With Capecitabine and Oxaliplatin vs Capecitabine for Stage II to III Rectal Cancer: A Randomized Clinical Trial

IMPORTANCE: Several studies have explored the efficacy and toxic effects of concurrent 5-fluorouracil (5-FU)– or capecitabine-based chemoradiotherapy (CRT) with or without oxaliplatin in the neoadjuvant setting. Addition of oxaliplatin to 5-FU or capecitabine elicited similar outcomes but with signi...

Descripción completa

Detalles Bibliográficos
Autores principales:	Li, Ning, Zhu, Yuan, Liu, Lu-Ying, Feng, Yan-Ru, Wang, Wen-Ling, Wang, Jun, Wang, Hao, Li, Gao-Feng, Tang, Yuan, Hu, Chen, Liu, Wen-Yang, Ren, Hua, Wang, Shu-Lian, Wang, Wei-Hu, Song, Yong-Wen, Liu, Yue-Ping, Fang, Hui, Tang, Yu, Lu, Ning-Ning, Chen, Bo, Qi, Shu-Nan, Liu, Xin-Fan, Li, Ye-Xiong, Jin, Jing
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	American Medical Association 2021
Materias:	Original Investigation
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8634060/ https://www.ncbi.nlm.nih.gov/pubmed/34846525 http://dx.doi.org/10.1001/jamanetworkopen.2021.36116

Ejemplares similares

Interim analysis of postoperative chemoradiotherapy with capecitabine and oxaliplatin versus capecitabine alone for pathological stage II and III rectal cancer: a randomized multicenter phase III trial
por: Feng, Yan-Ru, et al.
Publicado: (2016)

Retrospective study of preoperative chemoradiotherapy with capecitabine versus capecitabine plus oxaliplatin for locally advanced rectal cancer
por: Yang, Xiao-Hui, et al.
Publicado: (2020)

Preoperative chemoradiotherapy with capecitabine and triweekly oxaliplatin versus capecitabine monotherapy for locally advanced rectal cancer: a propensity-score matched study
por: Li, Anchuan, et al.
Publicado: (2022)

Prospective clinical study of capecitabine plus oxaliplatin concurrent chemoradiotherapy after radical resection of rectal cancer
por: Chen, Wanghua, et al.
Publicado: (2018)

Postoperative Capecitabine with Concurrent Intensity-Modulated Radiotherapy or Three-Dimensional Conformal Radiotherapy for Patients with Stage II and III Rectal Cancer
por: Lu, Ning-Ning, et al.
Publicado: (2015)

Dose-finding study of oxaliplatin associated to capecitabine-based preoperative chemoradiotherapy in locally advanced rectal cancer
por: Bruera, Gemma, et al.
Publicado: (2018)

Addition of oxaliplatin to capecitabine-based preoperative chemoradiotherapy for locally advanced rectal cancer: Long-term outcome of a phase II study
por: Peng, Jianhong, et al.
Publicado: (2017)

Prolonged Capecitabine Chemotherapy Following Capecitabine and Oxaliplatin (CAPOX) Regimen Chemotherapy Failed to Improve Survival of Stage III Colorectal Cancer After Radical Resection
por: Xu, Ju Ling, et al.
Publicado: (2019)

Efficacy and toxicity of capecitabine combined with intensity-modulated radiotherapy after D1/D2 lymph node dissection in patients with gastric cancer
por: Wang, Xin, et al.
Publicado: (2021)

Neoadjuvant Capecitabine and Oxaliplatin Before Concurrent Capecitabine and Radiation in Locally Advanced Rectal Cancers: Experience of a Cancer Hospital in Pakistan
por: Mansha, Muhammad Atif, et al.
Publicado: (2021)

Comparison of two preoperative chemoradiotherapy regimens for locally advanced rectal cancer: capecitabine alone versus capecitabine plus irinotecan
por: Lee, Sung Uk, et al.
Publicado: (2013)

Efficacy of preoperative chemotherapy regimens in patients with initially unresectable locally advanced gastric adenocarcinoma: capecitabine and oxaliplatin (XELOX) or with epirubicin (EOX)
por: Wang, Yan, et al.
Publicado: (2016)

Cost-effectiveness analysis of capecitabine monotherapy versus capecitabine plus oxaliplatin in elderly patients with advanced gastric cancer
por: Peng, Jingyuan, et al.
Publicado: (2018)

A multicenter, randomized trial comparing efficacy and safety of paclitaxel/capecitabine and cisplatin/capecitabine in advanced gastric cancer
por: Lu, Zhihao, et al.
Publicado: (2018)

Efficacy after preoperative capecitabine and oxaliplatin (XELOX) versus docetaxel, oxaliplatin and S1 (DOS) in patients with locally advanced gastric adenocarcinoma: a propensity score matching analysis
por: Wang, Yan, et al.
Publicado: (2018)

Adding Consolidation Capecitabine to Neoadjuvant Chemoradiotherapy for Locally Advanced Rectal Cancer: A Propensity-Matched Comparative Study
por: Fang, Yifang, et al.
Publicado: (2022)

Neoadjuvant chemoradiotherapy with capecitabine based regimen in locally advanced rectal cancer: A retrospective study
por: Li, Fei, et al.
Publicado: (2023)

Effect of Neoadjuvant Chemoradiotherapy with Capecitabine versus Fluorouracil for Locally Advanced Rectal Cancer: A Meta-Analysis
por: Liu, Guo-Chen, et al.
Publicado: (2016)

Capecitabine versus 5-fluorouracil in neoadjuvant chemoradiotherapy of locally advanced rectal cancer: A meta-analysis
por: Zhu, Jinfeng, et al.
Publicado: (2019)

Oxaliplatin/capecitabine vs oxaliplatin/infusional 5-FU in advanced colorectal cancer: the MRC COIN trial
por: Madi, A, et al.
Publicado: (2012)

Consolidation chemotherapy with capecitabine after neoadjuvant chemoradiotherapy in high-risk patients with locally advanced rectal cancer: Propensity score study
por: Sheng, Xue-Qing, et al.
Publicado: (2022)

A Phase II Study of Sequential Capecitabine Plus Oxaliplatin Followed by Docetaxel Plus Capecitabine in Patients With Unresectable Gastric Adenocarcinoma: The TCOG 3211 Clinical Trial
por: Chen, Ming-Huang, et al.
Publicado: (2016)

Preoperative Chemoradiotherapy with Capecitabine and Oxaliplatin in Locally Advanced Rectal Cancer. A Phase I–II Multicenter Study of the Dutch Colorectal Cancer Group
por: Hospers, Geke A., et al.
Publicado: (2007)

S-1-Based versus Capecitabine-Based Preoperative Chemoradiotherapy in the Treatment of Locally Advanced Rectal Cancer: A Matched-Pair Analysis
por: Su, Meng, et al.
Publicado: (2014)

Toxicity associated with capecitabine plus oxaliplatin in colorectal cancer before and after an institutional policy of capecitabine dose reduction
por: Baird, R, et al.
Publicado: (2011)

Cost-Effectiveness Analysis of Capecitabine Plus Oxaliplatin Versus Gemcitabine Plus Oxaliplatin as First-Line Therapy for Advanced Biliary Tract Cancers
por: Chen, Ruijia, et al.
Publicado: (2022)

Neoadjuvant oxaliplatin and capecitabine combined with bevacizumab plus radiotherapy for locally advanced rectal cancer: results of a single-institute phase II study
por: Yu, Xin, et al.
Publicado: (2018)

Helical Tomotherapy Combined with Capecitabine in the Preoperative Treatment of Locally Advanced Rectal Cancer
por: Huang, Ming-Yii, et al.
Publicado: (2014)

Capecitabine Plus Oxaliplatin Combination Therapy for Basal Cell Carcinoma
por: Rhee, Jiyoung, et al.
Publicado: (2019)

Bevacizumab Combined With Oxaliplatin/Capecitabine in Patient With Refractory and Recurrent Mucinous Adenocarcinoma of the Appendix: A Case Report
por: Liu, Wenzhi, et al.
Publicado: (2019)

Identification of biomarkers predicting the chemotherapeutic outcomes of capecitabine and oxaliplatin in patients with gastric cancer
por: Zhang, Yan, et al.
Publicado: (2020)

Efficacy and safety of neoadjuvant sintilimab, oxaliplatin and capecitabine in patients with locally advanced, resectable gastric or gastroesophageal junction adenocarcinoma: early results of a phase 2 study
por: Jiang, Haiping, et al.
Publicado: (2022)

Phase II study of anlotinib in combination with oxaliplatin and capecitabine for patients with RAS/BRAF wild-type metastatic colorectal adenocarcinoma as the first-line therapy
por: Liu, Yue, et al.
Publicado: (2022)

Metronomic capecitabine inhibits liver transplant rejection in rats by triggering recipients’ T cell ferroptosis
por: Wang, Hao, et al.
Publicado: (2023)

Economic comparison of capecitabine + oxaliplatin and 5-fluorouracil + oxaliplatin in the adjuvant treatment of colon cancer
por: Aitini, Enrico, et al.
Publicado: (2012)

Choice of Capecitabine or S1 in Combination with Oxaliplatin based on Thymidine Phosphorylase and Dihydropyrimidine Dehydrogenase Expression Status in Patients with Advanced Gastric Cancer
por: Xu, Rong, et al.
Publicado: (2019)

Prostate-specific antigen reduction after capecitabine plus oxaliplatin chemotherapy: A case report
por: Zou, Qian, et al.
Publicado: (2023)

Oxaliplatin plus Capecitabine in the Perioperative Treatment of Locally Advanced Gastric Adenocarcinoma in Combination with D2 Gastrectomy: NEO‐CLASSIC Study
por: Yu, Yiyi, et al.
Publicado: (2019)

Comparison of the effectiveness and toxicity of neoadjuvant chemotherapy regimens, capecitabine/epirubicin/cyclophosphamide vs 5-fluorouracil/epirubicin/cyclophosphamide, followed by adjuvant, capecitabine/docetaxel vs docetaxel, in patients with operable breast cancer
por: Zhang, Minmin, et al.
Publicado: (2016)

Prevention of oxaliplatin-related neurotoxicity by ω-3 PUFAs: A double-blind randomized study of patients receiving oxaliplatin combined with capecitabine for colon cancer
por: Zhang, Xinjie, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_ue2i6v8p8pa8tdj0gv1tp6jhj3